

December 7, 2022

Thomas Schuetz
Chief Executive Officer
Compass Therapeutics, Inc.
80 Guest Street
Suite 601
Boston, Massachusetts 02135

Therapeutics, Inc.
Statement on Form S-3
2022

Re: Compass
Registration
Filed December 2,
File No. 333-268652

Dear Thomas Schuetz:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Dillon Hagius at 202-551-7967 with any questions.

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

James Xu